
|Videos|January 6, 2014
Chemotherapy-Related Adverse Events Versus Immunotherapy-Related Adverse Events
Author(s)Matthew Burke, MBA, RN, MSN, APRN-BC
Matthew Burke, MBA, RN, MSN, APRN-BC, Oncology Nurse Practitioner/Melanoma and Renal Cell Carincoma, Yale New Haven Hospital, discusses the difference between adverse events caused by chemotherapy and immunotherapy.
Advertisement
Matthew Burke, MBA, RN, MSN, APRN-BC, Oncology Nurse Practitioner/Melanoma and Renal Cell Carincoma, Yale New Haven Hospital, discusses the difference between adverse events caused by chemotherapy and immunotherapy.
Clinical Pearls:
- Chemotherapy-related adverse events are usually limited to the time that the drug is in the patient’s body
- Immunotherapy agents cause modifications in the checkpoints of the immune system that may be permanent
- Because the immune system is altered during treatment, the severity of immunotherapy-related adverse events can be much worse than chemotherapy-related adverse events
- It is currently difficult to predict which patients will experience severe adverse events from immunotherapy treatment
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Growing Alcohol-Attributable Cancer Burden in US Reveals Prevention Gap
2
INBRX-106/Pembrolizumab Shows Efficacy in First-Line HNSCC
3
Four Approvals Reflect Growth in Hormone-Sensitive Prostate Cancer Treatment
4
Tarlatamab Plus Durvalumab Improves Survival in First-Line ES-SCLC
5







































